Yajing Wang

Yajing Wang

Auto-generated profile, based on publicly available information

Yajing Wang

Department of Obstetrics and Gynecology, West China Second University Hospital Sichuan University Chengdu Sichuan China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2025 in Lasers in Surgery and Medicine
Verified
Journal Article
Open access
DWDongmei Wei
Dongmei Wei
JMJian Meng
Jian Meng
QLQiao Li
Qiao Li
YWYajing Wang
Yajing Wang
YCYueyue Chen
Yueyue Chen
XNXiaoyu Niu
Xiaoyu Niu
Objectives: This study systematically reviews randomized controlled trials (RCTs) evaluating laser therapy for vulvar lichen sclerosus (VLS) to assess its efficacy and safety, aiming to inform clinical management and guideline development. Methods: RCTs on laser treatment for VLS were retrieved from PubMed, Embase, Web of Science, and Cochrane databases up to January 2025, limited to English literature. References from included studies were also screened. Data on study characteristics, laser parameters, outcome measures, measurement tools, and assessment time points were extracted and analyzed. Results: Seven RCTs (332 patients) reported 19 outcomes and 19 measurement tools, each used a total of 28 times. Symptoms and signs were most frequently reported and commonly measured using the Visual Analog Scale (VAS). Most trials indicated improvements in symptoms, signs, quality of life (QoL), and histology after laser therapy. Three studies reported greater symptom/sign improvement than topical corticosteroids ( p < 0.05), and three found higher patient satisfaction ( p < 0.05). Two studies showed good tolerability via VAS. Adverse events occurred in five studies (147 patients), including five mild cases (local irritation, blisters, urinary tract infection, itching, and pain). Due to heterogeneity and low study quality, a meta‐analysis was not performed. Conclusions: Laser therapy improves symptoms/signs, QoL, and histological outcomes in VLS, with good safety and tolerability. However, the evidence supporting its use as a monotherapy is limited, and benefits for anti‐inflammatory, anti‐fibrotic, scar‐preventive, or anticarcinogenic effects remain unproven. Large‐scale, long‐term, and high‐quality trials are needed, and future research should establish standardized Core Outcome and Measurement Sets to optimize VLS management.

5 July 2022 in Nursing in Critical Care
Verified
Journal Article
Closed access
YWYa Jing Wang
Ya Jing Wang
LLLei Lei
Lei Lei
YHYan Huang
Yan Huang

1 March 2026 in Lasers in Surgery and Medicine
Verified
Journal Article
Open access
PDF file
DWDongmei Wei
Dongmei Wei
JMJian Meng
Jian Meng
YZYanjun Zhu
Yanjun Zhu
QLQiao Li
Qiao Li
YWYajing Wang
Yajing Wang
XNXiaoyu Niu
Xiaoyu Niu
Background: Vulvar lichen simplex chronicus (VLSC) is a chronic inflammatory dermatosis that remains difficult to manage long term. Fractional CO 2 laser (FxCO 2 ) combined with topical corticosteroids (TCs) has emerged as a potential therapeutic strategy; however, high‐quality long‐term evidence remains limited. Objective: To evaluate the long‐term efficacy and safety of FxCO 2 combined with TC in patients with VLSC. Study Design: This retrospective single‐center study included 172 patients with biopsy‐confirmed VLSC treated between 2016 and 2024. All patients received at least one FxCO 2 + TC treatment session. Primary outcomes included pruritus improvement, recurrence, and subjective symptom relief. Secondary outcomes assessed patient satisfaction, treatment adherence, and adverse events. Results: FxCO 2 combined with TC treatment was effective, achieving an initial pruritus improvement rate of 90.12% (155/172). Subjective symptom improvement was reported by 91.86% (158/172) of patients, and patient satisfaction was 88.95% (153/172). Among those who improved, 50.58% (80/155) achieved improvement after 3 treatments, and the median duration of improvement was 18.0 months (range, 12–54 months). The recurrence rate was 14.84% (23/155), with a median time to recurrence of 36.0 months (range, 12–60 months). Adverse events occurred in 15.70% (27/172) of patients, with dryness being the most common (6.40%, 11/172). No clinical signs of deterioration or atypical progression were noted throughout the follow‐up. Conclusion: FxCO 2 combined with TC treatment is effective and well tolerated in women with VLSC, providing long‐term symptom relief with low recurrence and acceptable safety. This combined approach may represent a promising therapeutic option for managing intense pruritus associated with VLSC.

5 April 2026 in Lasers in Surgery and Medicine
Verified
Journal Article
Open access
PDF file
QLQiao Li
Qiao Li
JMJian Meng
Jian Meng
YWYajing Wang
Yajing Wang
YCYueyue Chen
Yueyue Chen
XNXiaoyu Niu
Xiaoyu Niu
DWDongmei Wei
Dongmei Wei
Background: Vaginal relaxation syndrome (VRS) is a common condition that adversely affects women's quality of life. Conventional non‐surgical therapies provide limited benefit for patients with mild to moderate disease. Fractional CO 2 laser (FxCO 2 ) therapy has emerged as a minimally invasive treatment option; however, its long‐term efficacy and safety remain to be fully elucidated. Objective: To prospectively evaluate the efficacy and safety of FxCO 2 in women with mild to moderate VRS. Methods: This prospective self‐controlled study enrolled 101 women diagnosed with mild to moderate VRS. All participants underwent three sessions of FxCO 2 treatment at 4‐week intervals. Clinical outcomes were assessed at baseline and at 1, 3, 6, and 12 months after the final treatment using the Female Sexual Function Index (FSFI), Vaginal Laxity Questionnaire (VLQ), and Vaginal Health Index (VHI). Adverse events were recorded throughout the follow‐up period. Results: All primary outcome measures improved following treatment. The mean FSFI total score increased from 21.4 to 25.9, the VLQ score improved from 2.68 to approximately 3.0, and the VHI score increased from 17.0 to 19.25 (all p < 0.001). Subgroup analyses indicated that treatment efficacy was not significantly influenced by parity, age, or the presence of concomitant urinary incontinence. Only mild and transient adverse events were reported, all of which resolved spontaneously. Conclusions: FxCO 2 therapy effectively improves sexual function, subjective vaginal tightness, and vaginal mucosal health in women with vaginal relaxation syndrome. The short‐term efficacy is favorable, with no significant safety concerns observed.

20 May 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
EKErik H. Klontz
Erik H. Klontz
JOJuliet Obi
Juliet Obi
YWYajing Wang
Yajing Wang
GGGabrielle Glendening
Gabrielle Glendening
JCJahid Carr
Jahid Carr
GSGreg Snyder
Greg Snyder
Toll-like and Interleukin-1/18 receptor resistance (TIR) domain-containing proteins function as important signaling and immune regulatory molecules. TIR domain-containing proteins identified in eukaryotic and prokaryotic species also exhibit NAD+ hydrolase activity in select bacteria, plants, and mammalian cells. We report the crystal structure of the Acinetobacter baumannii TIR domain protein (AbTir-TIR) with confirmed NAD + hydrolysis and map the conformational effects of its interaction with NAD + using HDX-MS. NAD + results in mild decreases in deuterium uptake at the dimeric interface. In addition, AbTir-TIR exhibits EX1 kinetics indicative of large cooperative conformational changes which are slowed down upon substrate binding. Additionally, we have developed label-free imaging using 2pFLIM which shows differences in bacteria expressing native and mutant NAD+ hydrolase-inactivated AbTir-TIR EA protein. Our observations are consistent with substrate-induced conformational changes reported in other TIR model systems with NAD+ hydrolase activity. These studies provide further insight into bacterial TIR protein mechanisms and their varying roles in biology.